Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista de Atenção à Saúde |
Texto Completo: | http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439 |
Resumo: | Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology. |
id |
USCS-3_d3cba65fa105d63c9fc49b15760d2cd2 |
---|---|
oai_identifier_str |
oai:ojs2.seer.uscs.edu.br:article/4439 |
network_acronym_str |
USCS-3 |
network_name_str |
Revista de Atenção à Saúde |
repository_id_str |
|
spelling |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic reviewAtividade terapêutica do anticorpo monoclonal evolocumab contra proteínas PCSK9 na modulação do colesterol LDL: revisão sistemáticaHiperlipoproteinemia tipo IILipoproteínas LDLInfarto do miocárdioPCSK9Hyperlipoproteinemia type IILDL lipoproteinsMyocardial infarctionPCSK9Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology.Introdução: As alterações de hipercolesterolemia podem gerar patologias como o infarto agudo do miocárdio (IAM). No entanto, nem sempre o aumento do colesterol é ocasionado apenas pela má alimentação e pelo estilo de vida; grupos como o da hipercolesterolemia familiar (HF) têm valores séricos aumentados por alterações genéticas e, nesses casos, as medicações antidislipidemiantes tradicionais não são eficazes. Objetivo: Compilar e discutir os resultados obtidos pela literatura atual que se debruça sobre o anticorpo monoclonal evolocumab para diminuição do PCSK9. Materiais e métodos: Revisão sistemática dos resultados de testes feitos em humanos com idade superior a 19 anos publicados em língua inglesa há menos de cinco anos, utilizando a base de dados PubMed. Resultados:Foram encontrados 135 artigos, dentre os quais nove foram selecionados por critérios de exclusão. Discussão: Os resultados demonstraram que o poder farmacológico do anticorpo evolocumab tem notória valia diante de terapêuticas habituais e placebos para pacientes que não apresentam resposta significativa com as terapias atuais. Conclusão: Por se tratar de um estudo bastante recente, ainda há necessidade de mais pesquisas que demonstrem eventuais reações adversas e interações com outros medicamentos. No entanto, já está em evidência uma grande vantagem para tratamentos futuros por preencher lacunas da farmacologia tradicional.Universidade Municipal de São Caetano do Sul - USCS2017-08-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo de Revisãoapplication/pdfhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/443910.13037/ras.vol15n52.4439Journal of Health Care; Vol. 15 No. 52 (2017); 72-77Revista de Atenção à Saúde; v. 15 n. 52 (2017); 72-772359-4330reponame:Revista de Atenção à Saúdeinstname:Universidade Municipal de São Caetano do Sul (USCS)instacron:USCSporhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439/pdfFerreira, Mario Henrique QuimRibeiro, Rodrigo Metzker PereiraFunes, Ana Beatriz AntunesFaustino, Bruna Mohine OliveiraSegato, Fernanda CardinMattos, Luana Lozano Cardoso deCarvalho, Thais Caroline dos SantosPrada Filho, Carlos Funesinfo:eu-repo/semantics/openAccess2017-08-18T22:32:36Zoai:ojs2.seer.uscs.edu.br:article/4439Revistahttps://seer.uscs.edu.br/index.php/revista_ciencias_saudePUBhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/oaieditoria.ras@online.uscs.edu.br || vera.basso@online.uscs.edu.br2359-43302359-4330opendoar:2017-08-18T22:32:36Revista de Atenção à Saúde - Universidade Municipal de São Caetano do Sul (USCS)false |
dc.title.none.fl_str_mv |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review Atividade terapêutica do anticorpo monoclonal evolocumab contra proteínas PCSK9 na modulação do colesterol LDL: revisão sistemática |
title |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
spellingShingle |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review Ferreira, Mario Henrique Quim Hiperlipoproteinemia tipo II Lipoproteínas LDL Infarto do miocárdio PCSK9 Hyperlipoproteinemia type II LDL lipoproteins Myocardial infarction PCSK9 |
title_short |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
title_full |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
title_fullStr |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
title_full_unstemmed |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
title_sort |
Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review |
author |
Ferreira, Mario Henrique Quim |
author_facet |
Ferreira, Mario Henrique Quim Ribeiro, Rodrigo Metzker Pereira Funes, Ana Beatriz Antunes Faustino, Bruna Mohine Oliveira Segato, Fernanda Cardin Mattos, Luana Lozano Cardoso de Carvalho, Thais Caroline dos Santos Prada Filho, Carlos Funes |
author_role |
author |
author2 |
Ribeiro, Rodrigo Metzker Pereira Funes, Ana Beatriz Antunes Faustino, Bruna Mohine Oliveira Segato, Fernanda Cardin Mattos, Luana Lozano Cardoso de Carvalho, Thais Caroline dos Santos Prada Filho, Carlos Funes |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Ferreira, Mario Henrique Quim Ribeiro, Rodrigo Metzker Pereira Funes, Ana Beatriz Antunes Faustino, Bruna Mohine Oliveira Segato, Fernanda Cardin Mattos, Luana Lozano Cardoso de Carvalho, Thais Caroline dos Santos Prada Filho, Carlos Funes |
dc.subject.por.fl_str_mv |
Hiperlipoproteinemia tipo II Lipoproteínas LDL Infarto do miocárdio PCSK9 Hyperlipoproteinemia type II LDL lipoproteins Myocardial infarction PCSK9 |
topic |
Hiperlipoproteinemia tipo II Lipoproteínas LDL Infarto do miocárdio PCSK9 Hyperlipoproteinemia type II LDL lipoproteins Myocardial infarction PCSK9 |
description |
Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-08-17 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigo de Revisão |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439 10.13037/ras.vol15n52.4439 |
url |
http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439 |
identifier_str_mv |
10.13037/ras.vol15n52.4439 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439/pdf |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Municipal de São Caetano do Sul - USCS |
publisher.none.fl_str_mv |
Universidade Municipal de São Caetano do Sul - USCS |
dc.source.none.fl_str_mv |
Journal of Health Care; Vol. 15 No. 52 (2017); 72-77 Revista de Atenção à Saúde; v. 15 n. 52 (2017); 72-77 2359-4330 reponame:Revista de Atenção à Saúde instname:Universidade Municipal de São Caetano do Sul (USCS) instacron:USCS |
instname_str |
Universidade Municipal de São Caetano do Sul (USCS) |
instacron_str |
USCS |
institution |
USCS |
reponame_str |
Revista de Atenção à Saúde |
collection |
Revista de Atenção à Saúde |
repository.name.fl_str_mv |
Revista de Atenção à Saúde - Universidade Municipal de São Caetano do Sul (USCS) |
repository.mail.fl_str_mv |
editoria.ras@online.uscs.edu.br || vera.basso@online.uscs.edu.br |
_version_ |
1798042262039429120 |